Alnylam Pharmaceuticals, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2025: USD -45.11 M

Alnylam Pharmaceuticals, Inc. Operating Cash Flow is USD -45.11 M for the Trailing 12 Months (TTM) ending March 31, 2025, a -123.85% change year over year. Operating cash flow is cash generated from the company’s regular business operations.
  • Alnylam Pharmaceuticals, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 189.12 M, a -135.25% change year over year.
  • Alnylam Pharmaceuticals, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2023 was USD -536.56 M, a -7.05% change year over year.
  • Alnylam Pharmaceuticals, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2022 was USD -577.23 M, a -4.51% change year over year.
  • Alnylam Pharmaceuticals, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2021 was USD -604.46 M, a 79.86% change year over year.
Key Data
Date Operating Cash Flow Capital Expenditure Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities